中国临床肿瘤学会

讲者：盛伟琪

单位：复旦大学附属肿瘤医院

$MagnetisMM-1: Phase 1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma$

讲者：Michael Chu

单位：Cross Cancer Institute, Edmonton, Alberta, Canada

$Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin$

讲者：Evangelos Terpos

单位：National and Kapodistrian University of Athens School of Medicine, Athens, Greece

$Characterization of ocular adverse events in patients receiving belantamab mafadotin for ≥12 months: Post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma$

讲者：Sagar Lonial

单位：Emory University, Winship Cancer Institute, Atlanta, GA, USA

$DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)$

讲者：Rakesh Popat

单位：University College London Hospitals, NHS Foundation Trust, London, UK

$Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study$

讲者：Laurie Eliason

单位：GlaxoSmithKline, Upper Providence, PA, USA

讲者：金晶

单位：中国医学科学院肿瘤医院

讲者：肖健

单位：中山大学附属第六医院

讲者：李国新

单位：南方医科大学南方医院

讲者：沈琳

单位：北京大学肿瘤医院